Raphaelle Richieri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4263771/publications.pdf

Version: 2024-02-01

70 papers

1,679 citations

279701 23 h-index 315616 38 g-index

79 all docs 79 docs citations

79 times ranked 2654 citing authors

#	Article	IF	CITATIONS
1	Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology, 2014, 231, 3663-3676.	1.5	278
2	Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset. Schizophrenia Bulletin, 2016, 42, 1290-1302.	2.3	82
3	Quality of life among caregivers of individuals with affective disorders. Journal of Affective Disorders, 2012, 136, 660-665.	2.0	70
4	Predictive value of brain perfusion SPECT for rTMS response in pharmacoresistant depression. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1715-1722.	3.3	63
5	A structural equation modelling approach to explore the determinants of quality of life in schizophrenia. Schizophrenia Research, 2016, 171, 27-34.	1.1	61
6	Quality of life among caregivers of patients with schizophrenia: a cross-cultural comparison of Chilean and French families. BMC Family Practice, 2012, 13, 42.	2.9	57
7	Parieto-temporal alpha EEG band power at baseline as a predictor of antidepressant treatment response with repetitive Transcranial Magnetic Stimulation: A preliminary study. Journal of Affective Disorders, 2012, 137, 156-160.	2.0	56
8	Deep brain stimulation for refractory obsessive-compulsive disorder (OCD): emerging or established therapy?. Molecular Psychiatry, 2021, 26, 60-65.	4.1	54
9	Maintenance transcranial magnetic stimulation reduces depression relapse: A propensity-adjusted analysis. Journal of Affective Disorders, 2013, 151, 129-135.	2.0	53
10	Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia. Psychiatry Research, 2013, 210, 381-386.	1.7	46
11	Schizophrenia with preserved insight is associated with increased perfusion of the precuneus. Journal of Psychiatry and Neuroscience, 2012, 37, 297-304.	1.4	45
12	Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset. Schizophrenia Research, 2017, 182, 84-89.	1.1	41
13	Neurocognition, Insight and Medication Nonadherence in Schizophrenia: A Structural Equation Modeling Approach. PLoS ONE, 2012, 7, e47655.	1.1	36
14	Innovative mechanisms of action for pharmaceutical cognitive enhancement: A systematic review. Psychiatry Research, 2015, 229, 12-20.	1.7	36
15	Sensory gating in adult with attention-deficit/hyperactivity disorder: Event-evoked potential and perceptual experience reports comparisons with schizophrenia. Biological Psychology, 2015, 107, 16-23.	1.1	32
16	Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence. Journal of Clinical Psychiatry, 2016, 77, e1130-e1136.	1.1	31
17	Perceptual abnormalities related to sensory gating deficit are core symptoms in adults with ADHD. Psychiatry Research, 2015, 230, 357-363.	1.7	29
18	Sensory Gating Capacity and Attentional Function in Adults With ADHD: A Preliminary Neurophysiological and Neuropsychological Study. Journal of Attention Disorders, 2019, 23, 1199-1209.	1.5	27

#	Article	IF	CITATIONS
19	Do schizophrenia patients with low P50-suppression report more perceptual anomalies with the sensory gating inventory?. Schizophrenia Research, 2014, 157, 157-162.	1.1	26
20	Functional involvement of superior temporal sulcus in quality of life of patients with schizophrenia. Psychiatry Research - Neuroimaging, 2012, 202, 155-160.	0.9	25
21	Changes in dorsolateral prefrontal connectivity after rTMS in treatment-resistant depression: a brain perfusion SPECT study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1051-1055.	3.3	25
22	Elevated C-reactive protein is associated with sensory gating deficit in schizophrenia. Schizophrenia Research, 2015, 165, 94-96.	1.1	24
23	Results of Gamma Knife anterior capsulotomy for refractory obsessive-compulsive disorder: results in a series of 10 consecutive patients. Journal of Neurosurgery, 2019, 131, 376-383.	0.9	24
24	Improvement of health-related quality of life in depression after transcranial magnetic stimulation in a naturalistic trial is associated with decreased perfusion in precuneus. Health and Quality of Life Outcomes, 2012, 10, 87.	1.0	23
25	Neurophysiological correlates of metabolic syndrome and cognitive impairment in schizophrenia: A structural equation modeling approach. Psychoneuroendocrinology, 2014, 50, 95-105.	1.3	22
26	Equivalent brain SPECT perfusion changes underlying therapeutic efficiency in pharmacoresistant depression using either high-frequency left or low-frequency right prefrontal rTMS. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 364-370.	2.5	21
27	Validation of a functional remission threshold for the Functional Remission of General Schizophrenia (FROGS) scale. Comprehensive Psychiatry, 2013, 54, 1016-1022.	1.5	21
28	<p>Deep brain stimulation in the treatment of obsessive-compulsive disorder: current perspectives</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1259-1272.	1.0	21
29	Prevalence of Metabolic Syndrome and Associated Factors in a Cohort of Individuals With Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2019, 80, .	1.1	21
30	Neural substrate of quality of life in patients with schizophrenia: a magnetisation transfer imaging study. Scientific Reports, 2015, 5, 17650.	1.6	17
31	Childhood maltreatment and clinical severity of treatmentâ€resistant depression in a French cohort of outpatients (FACEâ€DR): Oneâ€year followâ€up. Depression and Anxiety, 2020, 37, 365-374.	2.0	16
32	Mediation Analyses of Insight, Quality of Life, Depression, and Suicidality. Journal of Clinical Psychiatry, 2018, 79, .	1.1	16
33	Positive clinical effects of gamma knife capsulotomy in a patient with deep brain stimulation-refractory Tourette Syndrome and Obsessive Compulsive Disorder. Clinical Neurology and Neurosurgery, 2018, 170, 34-37.	0.6	15
34	Effects of Clozapine on Perceptual Abnormalities and Sensory Gating. Journal of Clinical Psychopharmacology, 2015, 35, 184-187.	0.7	13
35	Does sensory gating have a protective effect against hallucinatory behavior in schizophrenia?. Clinical Neurophysiology, 2016, 127, 1746-1748.	0.7	13
36	Are Cardiovascular Risk Factors Associated with Verbal Learning and Memory Impairment in Patients with Schizophrenia? A Cross-Sectional Study. Cardiovascular Psychiatry and Neurology, 2012, 2012, 1-8.	0.8	11

3

#	Article	IF	Citations
37	Quality of life and other outcome measures in caregivers of patients with schizophrenia. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 641-649.	0.7	11
38	Validation of the French sensory gating inventory: A confirmatory factor analysis. Psychiatry Research, 2014, 220, 1106-1112.	1.7	11
39	Determinants of brain SPECT perfusion and connectivity in treatment-resistant depression. Psychiatry Research - Neuroimaging, 2015, 231, 134-140.	0.9	11
40	Childhood Trauma increases suicidal behaviour in a treatment-resistant depression population: a FACE-DR report. Journal of Psychiatric Research, 2021, 135, 20-27.	1.5	11
41	Multiple Realities and Hybrid Objects: A Creative Approach of Schizophrenic Delusion. Frontiers in Psychology, 2018, 9, 107.	1.1	10
42	Treatment-Resistant Depression in a Real-World Setting: First Interim Analysis of Characteristics, Healthcare Resource Use, and Utility Values of the FondaMental Cohort. Brain Sciences, 2020, 10, 962.	1.1	9
43	Unmasking Partial Seizure after Deep Brain Stimulation for Treatment-Resistant Depression: A Case Report. Brain Stimulation, 2016, 9, 636-638.	0.7	8
44	Fiabilité des références diagnostiques du Recueil d'Informations Médicalisées en Psychiatrie. Sante Publique, 2012, Vol. 23, 31-38.	0.0	8
45	Predict the outcome of depression after rTMS using neuroimaging: Issue of response or non-response?. Brain Stimulation, 2013, 6, 95-96.	0.7	7
46	Advanced Paternal Age is associated with earlier schizophrenia onset in offspring. Results from the national multicentric FACE-SZ cohort. Psychiatry Research, 2017, 254, 218-223.	1.7	7
47	Predictive value of dorso-lateral prefrontal connectivity for rTMS response in treatment-resistant depression: A brain perfusion SPECT study. Brain Stimulation, 2018, 11, 1093-1097.	0.7	7
48	Brain SPECT perfusion and PET metabolism as discordant biomarkers in major depressive disorder. EJNMMI Research, 2020, 10, 121.	1.1	7
49	Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the real-world FACE-TRD national cohort. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 114, 110479.	2.5	7
50	Resistant bipolar depressive disorder: case analysis of adjunctive transcranial magnetic stimulation efficiency in medical comorbid conditions. Bipolar Disorders, 2014, 16, 211-213.	1.1	6
51	Association of metabolic syndrome with sensory gating deficits in patients with chronic schizophrenia. Psychoneuroendocrinology, 2015, 57, 125-133.	1.3	6
52	Toward a transdiagnostic tool to evaluate depressive symptoms across mental disorders: Validation of the Calgary depression rating scale in patients with major depressive disorder. Psychiatry Research, 2018, 268, 68-71.	1.7	6
53	Brain PET metabolic substrate of TMS response in pharmaco-resistant depression. Brain Stimulation, 2020, 13, 683-685.	0.7	6
54	Peripheral inflammation is associated with brain SPECT perfusion changes in schizophrenia. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 905-912.	3.3	6

#	Article	IF	CITATIONS
55	Functional brain substrate of quality of life in patients with schizophrenia: A brain SPECT multidimensional analysis. Psychiatry Research - Neuroimaging, 2016, 249, 67-75.	0.9	5
56	Double cone coil rTMS efficacy for treatment-resistant depression: AÂprospective randomized controlled trial. Brain Stimulation, 2020, 13, 256-258.	0.7	5
57	Perceptually or conceptually driven recognition: On the specificities of the memory deficit in schizophrenia. Psychiatry Research, 2015, 225, 493-500.	1.7	4
58	A Case of Recovery After Delayed Intracranial Hemorrhage After Deep Brain Stimulation for Treatment-Resistant Depression. Biological Psychiatry, 2018, 83, e11-e13.	0.7	4
59	Psychiatric disability as mediator of the neurocognition-functioning link in schizophrenia spectrum disorders: SEM analysis using the Evaluation of Cognitive Processes involved in Disability in Schizophrenia (ECPDS) scale. Schizophrenia Research, 2018, 201, 196-203.	1.1	4
60	Relationship between childhood physical abuse and clinical severity of treatment-resistant depression in a geriatric population. PLoS ONE, 2021, 16, e0250148.	1.1	4
61	Screening for cognitive deficits with the Evaluation of Cognitive Processes involved in Disability in Schizophrenia scale. Clinical Rehabilitation, 2019, 33, 113-119.	1.0	3
62	The Validity of the SQoL-18 in Patients with Bipolar and Depressive Disorders: A Psychometric Study from the PREMIUM Project. Journal of Clinical Medicine, 2022, 11, 743.	1.0	3
63	Neuroleptic malignant syndrome following reintroduction of an antipsychotic after overdose. BMJ Case Reports, 2018, 2018, bcr-2017-223922.	0.2	2
64	Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 703-714.	1.3	2
65	Defining functioning levels in patients with schizophrenia: A combination of a novel clustering method and brain SPECT analysis. Psychiatry Research - Neuroimaging, 2017, 270, 32-38.	0.9	1
66	Single-Photon Emission Computed Tomography Findings in a Patient With Fahr Disease Associated With a Schizophrenia-Like Psychosis. Journal of Clinical Psychiatry, 2013, 74, e431-e432.	1.1	1
67	Brain PET imaging in psychiatric disorders. , 2021, , .		1
68	Left Temporopolar Impairment in a Case of Posttraumatic Hypersomnia. Journal of Head Trauma Rehabilitation, 2013, 28, 473-475.	1.0	0
69	Successful Electroconvulsive Therapy for a Patient With McArdle Disease. Journal of ECT, 2017, 33, e36-e37.	0.3	0
70	Vagal Nerve Stimulation (VNS): A practical option to discontinue rTMS in treatment-resistant depression?. Neurology Psychiatry and Brain Research, 2019, 31, 29-31.	2.0	0